A BUSINESS BUILT ON
THE PURSUIT OF UNUSUAL, RISK ADJUSTED PERFORMANCE

Morana became an advisor and consultant to the Park Vale Group in 2012 to lead the biotechnology expertise developing and managing investment deals and funds in conjunction with Park Vale in this attractive investment field. Morana is the Founder and Managing Partner of F2 Ventures family of funds established from 2002.

Morana has extensive experience within both public and private equity markets. Aside from F2 Ventures, during 2004 to February 2008 she managed a public market biotech fund allocation for one of the leading hedge funds in the US.

In addition, until March of 2007, she was a Venture Partner at MPM Capital, where she was a principal fundraiser and investor for BioVentures III, a billion US dollar equities fund. Within MPM Capital apart from being on the investment side, she has also worked closely with portfolio companies both in fund raising directly for companies and in attaining critical business development milestones. Prior to joining MPM in 2000, Morana was at Banque Syz & Co in Geneva, where she led the bank’s investment activities in life sciences investments, including analysis of the biotech sector and due diligence on the biotech fund managers. In addition, she was a part of newly established alternative investments team, whereby she was responsible for new product structuring. Prior to that, Morana worked for Covance Central Laboratories as a Business Development Manager.

Morana holds an Executive M.B.A. from Stanford-NUS, and was a postdoctoral fellow at Harvard University, Department for Developmental Biology, where she worked on protein uncaging. She received her Ph.D. in Biophysical Chemistry at University of Cambridge. Dr. Jovan has published numerous articles on the biotechnology sector for leading European financial journals and sits on the board of private and public life science companies.

Back To Overview

Biotechnology Investments

The Park Vale Capital biotechnology team is currently focusing on investments in companies engaged in late stage biotechnology and pharma development selected from their extensive network of deal flow.